Advertisement

Topics

Angelman Syndrome Foundation Company Profile

01:07 EST 20th November 2017 | BioPortfolio

Since 1996, the Angelman Syndrome Foundation has funded 59 research grants totaling more than $3.5 million. The Angelman Syndrome Foundation has awarded a majority of these funds ($3.3 million) beginning in 2005. For more information on the Foundation, please visit www.angelman.org.


News Articles [1053 Associated News Articles listed on BioPortfolio]

Agilis Presents Data from its Gene Therapy Program for Angelman Syndrome

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Agilis Biotherapeutics, Inc. (Agilis), a biotechnology company advancing innovative DNA therapeutics for rare genetic diseases that affect the central nerv...

Pharmaceutical giant Roche funds concept study aiming to find cure for Angelman syndrome

A collaborative group of parent-driven organizations seeking a cure for Angelman syndrome has teamed up with F. Hoffmann-La Roche Ltd, one of the world’s largest pharmaceutical and diagnostics compa...

Agilis Biotherapeutics Announces Presentations on Angelman Syndrome Program at ESGCT and NORD ...

Read more...

Led by Steven Taylor, the Sjögren’s Syndrome Foundation is raising awareness of a little-known autoimmune disease

Steven Taylor’s role as CEO of the Sjögren’s Syndrome Foundation is more than just a job; it’s a passion. Taylor has seen firsthand how Sjögren’s syndrome can impact people – his own mothe...

Agilis Biotherapeutics Announces Presentations on Angelman Syndrome Program at ESGCT and NORD Rare Disease Summit

Agilis Biotherapeutics, Inc. (Agilis), a biotechnology company advancing innovative DNA therapeutics for rare genetic diseases that affect the central nervous system (CNS), announ...

Cushing's Syndrome Market Insights, Epidemiology and Market Forecast2023 [Report Updated: 01022017] Prices from USD $4950

DelveInsight's Cushing Syndrome Market Insights, Epidemiology and Market Forecast 2023 7MM Reports provides an overview of the disease and global market size of the Cushing Syndrome for the 7MM. It...

How to Get Over Impostor Syndrome as a New Graduate Student

You made it. You got into the grad school of your dreams! You worked hard, you spent hours working on your application, bravely navigated your way through the interview and you now are here. So, why d...

Stand Up To Cancer, St. Baldrick's Foundation hail green light for CAR T cell therapy

(Entertainment Industry Foundation) SU2C and St. Baldrick's welcomed ODAC's recommendation for FDA approval of the new CAR T therapy for a deadly form of leukemia, an approach whose development has al...

Drugs and Medications [450 Associated Drugs and Medications listed on BioPortfolio]

Esika [Ventura Corporation (San Juan, P.R)]

ēsika 3-in-1 Pro Make Up Foundation SPF 20

Sheer cover mineral foundation [Guthy-Renker LLC]

Sheer Cover Mineral Foundation SPF-15

Cle de peau beaute silky foundation i [SHISEIDO CO., LTD.]

CPB Silky Cream Foundation I

Cle de peau beaute foundation i [SHISEIDO CO., LTD.]

cle de peau BEAUTE Cream Foundation I

Shiseido perfect refining foundation [SHISEIDO AMERICA INC.]

SHISEIDO Perfect Refining Foundation

PubMed Articles [2614 Associated PubMed Articles listed on BioPortfolio]

Eye gaze and pupillary response in Angelman syndrome.

Angelman syndrome (AS) is a rare neurological disorder characterized by severe developmental disability, communication impairment, elevated seizure risk, and motor system abnormalities.

Sleep in children with Angelman syndrome: Parental concerns and priorities.

Angelman syndrome is a rare genetic syndrome, in which sleep disturbances are reported for 20-80% of individuals (Williams et al., 2006). This interview study delineated parental perceptions of sleep ...

Main causes of hospitalization in people with Angelman syndrome.

The objective was to describe the main causes of hospitalization in people with Angelman syndrome (AS).

Exploring Expressive Communication Skills in a Cross-Sectional Sample of Children and Young Adults With Angelman Syndrome.

This study explores data on expressive communication skills of 300 individuals aged 0.0-21.11 years with Angelman syndrome (AS). These data provide a composite portrait of communication skills in a la...

Hypersociability in the Angelman syndrome mouse model.

Deletions and reciprocal triplications of the human chromosomal 15q11-13 region cause two distinct neurodevelopmental disorders. Maternally-derived deletions or inactivating mutations of UBE3A, a 15q1...

Clinical Trials [3503 Associated Clinical Trials listed on BioPortfolio]

Study on Tolerability of Levodopa/Carbidopa in Children With Angelman Syndrome

This study is designed to determine the highest dose of levodopa/carbidopa that can be tolerated without any serious side effects by children with Angelman syndrome. It has been hypothesi...

Characterization of Angelman Syndrome

Angelman Syndrome (AS) is a developmental disorder that is caused by a deficiency of a maternally transmitted gene. It is inherited at birth, and affects movement, speech, and social demea...

Dietary Supplements for the Treatment of Angelman Syndrome

Angelman syndrome (AS) is a complex genetic disorder that affects the nervous system. The purpose of this study is to determine the effectiveness of certain dietary supplements in treating...

A Study in Adults With Angelman Syndrome

The purpose of the study is to assess the safety and tolerability of oral OV101 (gaboxadol) in adult subjects with Angelman syndrome. In addition, several exploratory efficacy outcome meas...

A Trial of Levodopa in Angelman Syndrome

This study is designed to determine whether levodopa will lead to an improvement in the development and tremor in children with Angelman syndrome (AS). It has been suggested that levodopa...

Companies [1442 Associated Companies listed on BioPortfolio]

Angelman Syndrome Foundation

Since 1996, the Angelman Syndrome Foundation has funded 59 research grants totaling more than $3.5 million. The Angelman Syndrome Foundation has awarded a majority of these funds ($3.3 million) beginn...

Foundation for Angelman Syndrome Therapeutics (FAST)

Angelman Syndrome (AS) was first described by Dr. Harry Angelman in 1965. Common symptoms include developmental delay and intellectual disabilities, happy demeanor, movement and balance disorder, seve...

The Angelman Syndrome Foundation

Sjogren's Syndrome Foundation

Founded in 1983, the Sjogren's Syndrome Foundation (SSF) provides patients with practical information and coping strategies that minimize the effects of Sjogren's syndrome. In addition, the Foundation...

Global Down Syndrome Foundation

The Global Down Syndrome Foundation is a public non-profit 501(c)(3) dedicated to significantly improving the lives of people with Down syndrome through research, medical care, ed...

More Information about "Angelman Syndrome Foundation" on BioPortfolio

We have published hundreds of Angelman Syndrome Foundation news stories on BioPortfolio along with dozens of Angelman Syndrome Foundation Clinical Trials and PubMed Articles about Angelman Syndrome Foundation for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Angelman Syndrome Foundation Companies in our database. You can also find out about relevant Angelman Syndrome Foundation Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record